Bruker - BRKR Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bruker in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BRKR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BRKR, but not buy additional shares or sell existing shares.
View BRKR analyst ratings or view top-rated stocks.

3 equities research analysts have issued 1-year price objectives for Bruker's stock. Their BRKR share price forecasts range from $60.00 to $90.00. On average, they predict the company's share price to reach $73.75 in the next twelve months. This suggests that the stock has a possible downside of 2.7%.
View analysts price targets for BRKR or view top-rated stocks among Wall Street analysts.

Bruker's stock was trading at $68.35 on January 1st, 2023. Since then, BRKR shares have increased by 10.9% and is now trading at $75.77.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our BRKR earnings forecast.

Bruker Co. (NASDAQ:BRKR) posted its quarterly earnings data on Thursday, February, 9th. The medical research company reported $0.74 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.02. The medical research company had revenue of $708.40 million for the quarter, compared to the consensus estimate of $697.68 million. Bruker had a net margin of 11.72% and a trailing twelve-month return on equity of 34.13%. The business's revenue was up 3.6% compared to the same quarter last year. During the same period last year, the firm earned $0.59 earnings per share.

Bruker declared a quarterly dividend on Friday, February 17th. Investors of record on Wednesday, March 1st will be paid a dividend of $0.05 per share on Friday, March 17th. This represents a $0.20 annualized dividend and a yield of 0.26%. The ex-dividend date of this dividend is Tuesday, February 28th.
Read our dividend analysis for BRKR.

ETFs with the largest weight of Bruker (NASDAQ:BRKR) stock in their portfolio include ProShares Nanotechnology ETF (TINY), Franklin Genomic Advancements ETF (HELX), Janus Henderson US Sustainable Equity ETF (SSPX), SPDR S&P Kensho New Economies Composite ETF (KOMP), SPDR Kensho Future Security ETF (FITE), Invesco DWA Healthcare Momentum ETF (PTH), First Trust Mid Cap US Equity Select ETF (RNMC) and Invesco ESG NASDAQ Next Gen 100 ETF (QQJG).

Bruker (NASDAQ:BRKR) pays an annual dividend of $0.20 per share and currently has a dividend yield of 0.27%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 10.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BRKR will have a dividend payout ratio of 6.99% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BRKR.

Bruker issued an update on its FY23 earnings guidance on Thursday, February, 9th. The company provided earnings per share (EPS) guidance of $2.52-2.57 for the period, compared to the consensus earnings per share estimate of $2.56. The company issued revenue guidance of $2.81-2.86 billion, compared to the consensus revenue estimate of $2.61 billion.

126 employees have rated Bruker Chief Executive Officer Frank H. Laukien on Glassdoor.com. Frank H. Laukien has an approval rating of 54% among the company's employees. This puts Frank H. Laukien in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 79.0% of employees surveyed would recommend working at Bruker to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bruker investors own include AbbVie (ABBV), CVS Health (CVS), Micron Technology (MU), Cisco Systems (CSCO), Intel (INTC), Alibaba Group (BABA), Walt Disney (DIS), Applied Materials (AMAT), Bank of America (BAC) and Bristol-Myers Squibb (BMY).

Bruker trades on the NASDAQ under the ticker symbol "BRKR."

Bruker's stock is owned by a number of retail and institutional investors. Top institutional investors include T. Rowe Price Investment Management Inc. (11.13%), Alliancebernstein L.P. (2.11%), Price T Rowe Associates Inc. MD (2.08%), Fuller & Thaler Asset Management Inc. (1.47%), Geode Capital Management LLC (1.15%) and TD Asset Management Inc (1.06%). Insiders that own company stock include Cynthia M Friend, Frank H Laukien, Marc A Kastner, Mark Munch and Richard A Packer.
View institutional ownership trends.

Shares of BRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BRKR stock can currently be purchased for approximately $75.77.

Bruker (NASDAQ:BRKR) has a market capitalization of $11.12 billion and generates $2.53 billion in revenue each year. The medical research company earns $296.60 million in net income (profit) each year or $1.99 on an earnings per share basis.

The company employs 8,525 workers across the globe.

Bruker's mailing address is 40 Manning Road, Billerica MA, 01821. The official website for the company is www.bruker.com. The medical research company can be reached via phone at (978) 663-3660, via email at investor.relations@bruker.com, or via fax at 978-663-5585.